臨床試験市場：相別、サービスタイプ別、治療領域別、用途別、試験デザイン見通し別、スポンサータイプ別、地域別、機会、予測、2017年～2031年

世界の臨床試験の市場規模は、2024年～2031年の予測期間中に7.17％のCAGRで拡大し、2023年の623億8,000万米ドルから2031年には1,085億5,000万米ドルに成長すると予測されています。臨床試験市場の成長は、製薬会社による研究開発投資の増加と希少疾患・希少疾病治療への注目の高まりによって牽引されると予想されます。これらの要素は、革新的研究と新たな治療に対する強いニーズを生み出し、市場成長をさらに促進します。

世界の臨床試験市場は、製薬企業による研究開発投資の増加によって大きな成長を遂げています。ニパウイルス感染症やラッサ熱のような慢性疾患と新疾患の両方の流行が拡大していることが、革新的な治療に対する需要を押し上げています。新興市場は、その費用対効果と多様な患者層により、極めて重要な市場となっています。さらに、開発を奨励する規制上の優遇措置に支えられ、希少疾患や希少疾病用医薬品が重視されるようになっています。遠隔医療やウェアラブルデバイスを含むデジタルヘルス技術の登場は、臨床試験の効率を向上させ、患者エンゲージメントを高めています。例えばAstraZeneca PLCは2023年11月、Evinovaと呼ばれる新たなイニシアチブを導入し、効率を高めコストを削減するデジタルソリューションを通じて臨床試験を強化することを目的としています。このような開発は、継続的な技術的進歩と進化する規制条件によって支えられています。

世界の臨床試験市場は、医薬品、医療機器、バイオテクノロジー、ヘルスケアITの研究開発投資の増加により、急速に成長しています。ICON plc、Biogen Inc.、Novartis AG、F. Hoffmann-La Roche AGなどの企業が最前線に立ち、技術革新を進め、臨床研究能力を拡大しています。彼らの貢献は、この分野のダイナミックな進化と拡大を際立たせています。さらに、遠隔医療やウェアラブルデバイスなどの医療技術の導入は、臨床試験プロセスを加速させ、患者の関与を高めています。例えば、Accenture PLCがクラウド上で臨床試験のシミュレーションにAIを活用するQuantHealth Ltd.に戦略的投資を行ったことは、研究開発資金がいかに治療法の開発を加速させ、プロセスをより迅速で費用対効果の高いものにしているかを示しています。こうした取り組みは、研究開発投資の増加が臨床試験市場の進展に大きな影響を与えていることを浮き彫りにしています。

当レポートでは、世界の臨床試験市場について調査し、市場の概要とともに、相別、サービスタイプ別、治療領域別、用途別、試験デザイン見通し別、スポンサータイプ別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の臨床試験市場の見通し、2017年～2031年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2023年
  • 相別
  • サービスタイプ別
  • 治療領域別
  • 用途別
  • 試験デザイン見通し別
  • スポンサータイプ別
  • 地域別

第5章 北米の臨床試験市場の見通し、2017年～2031年

第6章 欧州の臨床試験市場の見通し、2017年～2031年

第7章 アジア太平洋の臨床試験市場の見通し、2017年～2031年

第8章 南米の臨床試験市場の見通し、2017年～2031年

第9章 中東・アフリカの臨床試験市場の見通し、2017年～2031年

第10章 ポーターのファイブフォース分析

第11章 市場力学

第12章 市場の動向と発展

第13章 規制枠組みとイノベーション

第14章 ケーススタディ

第15章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要参入企業トップ10の情勢
  • Thermo Fisher Scientific Inc.
  • Novo Nordisk A/S
  • IQVIA, Inc.
  • Laboratory Corporation of America Holdings
  • Caidya
  • ICON plc
  • Medpace Holdings, Inc.
  • Parexel International Corporation
  • Charles River Laboratories International, Inc.
  • SGS Societe Generale de Surveillance SA

第16章 戦略的提言

第17章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 3. Global Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 4. Global Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 5. Global Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 6. Global Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 7. Global Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 8. Global Clinical Trials Market Share (%), By Region, 2017-2031F
• Figure 9. North America Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 10. North America Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 11. North America Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 12. North America Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 13. North America Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 14. North America Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 15. North America Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 16. North America Clinical Trials Market Share (%), By Country, 2017-2031F
• Figure 17. United States Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 18. United States Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 19. United States Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 20. United States Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 21. United States Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 22. United States Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 23. United States Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 24. Canada Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 25. Canada Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 26. Canada Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 27. Canada Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 28. Canada Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 29. Canada Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 30. Canada Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 31. Mexico Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 32. Mexico Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 33. Mexico Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 34. Mexico Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 35. Mexico Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 36. Mexico Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 37. Mexico Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 38. Europe Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 39. Europe Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 40. Europe Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 41. Europe Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 42. Europe Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 43. Europe Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 44. Europe Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 45. Europe Clinical Trials Market Share (%), By Country, 2017-2031F
• Figure 46. Germany Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 47. Germany Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 48. Germany Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 49. Germany Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 50. Germany Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 51. Germany Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 52. Germany Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 53. France Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 54. France Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 55. France Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 56. France Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 57. France Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 58. France Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 59. France Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 60. Italy Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 61. Italy Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 62. Italy Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 63. Italy Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 64. Italy Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 65. Italy Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 66. Italy Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 67. United Kingdom Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 68. United Kingdom Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 69. United Kingdom Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 70. United Kingdom Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 71. United Kingdom Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 72. United Kingdom Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 73. United Kingdom Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 74. Russia Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 75. Russia Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 76. Russia Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 77. Russia Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 78. Russia Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 79. Russia Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 80.
• Figure 81. Russia Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 82. Netherlands Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 83. Netherlands Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 84. Netherlands Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 85. Netherlands Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 86. Netherlands Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 87. Netherlands Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 88. Netherlands Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 89. Spain Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 90. Spain Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 91. Spain Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 92. Spain Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 93. Spain Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 94. Spain Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 95. Spain Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 96. Turkey Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 97. Turkey Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 98. Turkey Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 99. Turkey Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 100. Turkey Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 101. Turkey Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 102. Turkey Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 103. Poland Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 104. Poland Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 105. Poland Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 106. Poland Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 107. Poland Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 108. Poland Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 109. Poland Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 110. South America Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 111. South America Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 112. South America Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 113. South America Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 114. South America Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 115. South America Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 116. South America Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 117. South America Clinical Trials Market Share (%), By Country, 2017-2031F
• Figure 118. Brazil Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 119. Brazil Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 120. Brazil Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 121. Brazil Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 122. Brazil Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 123. Brazil Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 124. Brazil Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 125. Argentina Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 126. Argentina Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 127. Argentina Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 128. Argentina Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 129. Argentina Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 130. Argentina Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 131. Argentina Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 132. Asia-Pacific Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 133. Asia-Pacific Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 134. Asia-Pacific Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 135. Asia-Pacific Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 136. Asia-Pacific Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 137. Asia-Pacific Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 138. Asia-Pacific Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 139. Asia-Pacific Clinical Trials Market Share (%), By Country, 2017-2031F
• Figure 140. India Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 141. India Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 142. India Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 143. India Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 144. India Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 145. India Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 146. India Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 147. China Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 148. China Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 149. China Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 150. China Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 151. China Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 152. China Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 153. China Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 154. Japan Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 155. Japan Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 156. Japan Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 157. Japan Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 158. Japan Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 159. Japan Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 160. Japan Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 161. Australia Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 162. Australia Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 163. Australia Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 164. Australia Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 165. Australia Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 166. Australia Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 167. Australia Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 168. Vietnam Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 169. Vietnam Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 170. Vietnam Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 171. Vietnam Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 172. Vietnam Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 173. Vietnam Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 174. Vietnam Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 175. South Korea Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 176. South Korea Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 177. South Korea Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 178. South Korea Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 179. South Korea Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 180. South Korea Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 181. South Korea Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 182. Indonesia Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 183. Indonesia Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 184. Indonesia Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 185. Indonesia Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 186. Indonesia Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 187. Indonesia Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 188. Indonesia Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 189. Philippines Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 190. Philippines Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 191. Philippines Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 192. Philippines Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 193. Philippines Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 194. Philippines Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 195. Philippines Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 196. Middle East & Africa Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 197. Middle East & Africa Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 198. Middle East & Africa Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 199. Middle East & Africa Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 200. Middle East & Africa Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 201. Middle East & Africa Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 202. Middle East & Africa Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 203. Middle East & Africa Clinical Trials Market Share (%), By Country, 2017-2031F
• Figure 204. Saudi Arabia Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 205. Saudi Arabia Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 206. Saudi Arabia Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 207. Saudi Arabia Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 208. Saudi Arabia Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 209. Saudi Arabia Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 210. Saudi Arabia Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 211. UAE Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 212. UAE Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 213. UAE Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 214. UAE Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 215. UAE Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 216. UAE Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 217. UAE Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 218. South Africa Clinical Trials Market, By Value, In USD Billion, 2017-2031F
• Figure 219. South Africa Clinical Trials Market Share (%), By Phase, 2017-2031F
• Figure 220. South Africa Clinical Trials Market Share (%), By Service Type, 2017-2031F
• Figure 221. South Africa Clinical Trials Market Share (%), By Therapeutic Area, 2017-2031F
• Figure 222. South Africa Clinical Trials Market Share (%), By Application, 2017-2031F
• Figure 223. South Africa Clinical Trials Market Share (%), By Study Designs Outlook, 2017-2031F
• Figure 224. South Africa Clinical Trials Market Share (%), By Sponsor Type, 2017-2031F
• Figure 225. By Phase Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 226. By Service Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 227. By Therapeutic Area Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 228. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 229. By Study Designs Outlook Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 230. By Sponsor Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 231. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global clinical trials market is projected to witness a CAGR of 7.17% during the forecast period 2024-2031, growing from USD 62.38 billion in 2023 to USD 108.55 billion in 2031. The growth of the clinical trials market is expected to be driven by higher R&D investments from pharmaceutical companies coupled with rising focus on rare and orphan disease treatment. These elements will create a strong need for innovative research and new treatments, further driving the market growth.

The global clinical trials market is experiencing substantial growth, fueled by increased investments in research and development from pharmaceutical companies. The growing prevalence of both chronic and new diseases like Nipah virus infection and Lassa fever is boosting the demand for innovative treatments. Emerging markets are becoming crucial due to their cost-effectiveness and varied patient demographics. Moreover, there is a heightened emphasis on rare diseases and orphan drugs, backed by regulatory incentives that encourage their development. The advent of digital health technologies, including telemedicine and wearable devices, is improving trial efficiency and enhancing patient engagement. For instance, in November 2023, AstraZeneca PLC introduced a new initiative called Evinova, aimed at enhancing clinical trials through digital solutions that boost efficiency and cut costs. This development is supported by ongoing technological advancements and evolving regulatory conditions.

Rising Investments in R&D to Boost Market Growth

The global clinical trials market is growing rapidly, driven by increased R&D investments across pharmaceuticals, medical devices, biotechnology, and healthcare IT. Companies such as ICON plc, Biogen Inc., Novartis AG, and F. Hoffmann-La Roche AG are at the forefront, advancing innovation and expanding clinical research capabilities. Their contributions highlight the sector's dynamic evolution and expansion. In addition, the inclusion of health technologies such as telemedicine and wearable devices is accelerating the trial process and enhancing patient engagement. For instance, Accenture PLC's strategic investment in QuantHealth Ltd., a company that uses AI to simulate clinical trials in the cloud, demonstrates how R&D funding speeds up the development of treatments, making the process quicker and more cost-effective. These initiatives highlight the significant influence of rising R&D investment on the progress of the clinical trials market.

Increasing Demand for Advanced Treatments Drives Market Growth

Rising demand for novel treatment is a major factor propelling the growth of the clinical trials market. With patients and healthcare professionals demanding better approaches to care, pharmaceutical and biotech organizations are funding significant amounts towards the clinical research world to meet these demands. And that is driving an acceleration of the start-up phase for new clinical trials and exploration of newer drug compounds. For instance, in February 2024, IOVANCE Biotherapeutics, Inc. has received the United States FDA's approval for Amtagvi, a novel cancer therapy - tumor-infiltrating lymphocytes (TIL) therapy. Amtagvi is designed for metastatic melanoma patients who are not eligible for other treatment options. The treatment works by enhancing immune cells within tumors to improve their cancer-fighting capabilities. This development showcases how the pursuit of cutting-edge treatments drives the growth of the clinical trials market, encouraging the creation of innovative therapies and specialized trial services.

Dominance of Phase II Clinical Trial

Phase II clinical trials play a vital role in the growth of the global clinical trials market by evaluating the effectiveness of new treatments on a broader scale. The complexity of these trials drives the demand for advanced services and technologies, increasing the need for specialized management and data analysis. When successful, these trials can lead to faster regulatory approvals and attract additional investment. The larger patient populations involved enhance recruitment and engagement efforts. For instance, as per ClinicalTrials.gov, there are around 94,000 active clinical trials in the field of cancer, of which around 30,000 trials are in Phase II, accounting for 31% of the total ongoing trials as of August 2024.

North America Dominates the Global Clinical Trials Market

North America leads the clinical trials market due to its effective regulatory framework, substantial financial resources, cutting-edge research infrastructure, diverse patient populations, operational excellence, political and economic stability, and a strong focus on innovation and collaboration. These factors collectively establish an optimal environment for conducting high-quality clinical trials, reinforcing North America's pivotal role in advancing global medical research and development. There has been a significant change in the distribution of clinical trials by region. Over the past five years, there was a steady rise in the number of newly recruiting trials' registration in the North America region. According to the WHO data, as of 2022, 168,520 clinical trials were registered in the United States; while 34,041 clinical trials were conducted in Canada.

Future Market Scenario (2024-2031F)

The clinical trials market is poised for impressive gains with the burgeoning trend of personalized medicine which encompasses treatments that are developed specifically for patients based on their genetic profiles and biomarkers. This strategy supports new types of clinical trials, such as adaptive and basket trials, which save costs by being more efficient. Aligning trials with the needs of patients also supports patient recruitment and retention, improving data quality to produce better outcomes. The use of advanced technologies and genomic data will further streamline trials, while supportive regulatory frameworks will speed up approvals. For instance, GSK plc's collaboration with Tempus exemplifies this trend, as GSK utilizes Tempus' AI-driven platform and patient data to enhance trial design, accelerate enrolment, and identify drug targets, boosting R&D success and expediting personalized treatment delivery.

Key Players Landscape and Outlook

Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., IQVIA, Inc., Laboratory Corporation of America Holdings, Caidya, ICON plc, Medpace Holdings, Inc., Parexel International Corporation, SGS Societe Generale de Surveillance SA, and Fortrea Inc., among others, are some of the leading companies in the clinical trials market, generating the highest revenue from drugs sales recently. The global clinical trials market is competitive, with a huge number of players operating in the local markets as well. Regulatory approvals of company products, mergers and acquisitions, and collaborations are the most common market strategies that have been observed in recent times.

In February 2024, Medidata, a Dassault Systemes company specializing in clinical trial solutions, renewed its partnership with the PPD clinical research business of Thermo Fisher Scientific Inc. The renewed agreement includes the Medidata Platform, Medidata Adjudicate, and additional Medidata Rave products. This collaboration aims to enhance the PPD clinical research business's capabilities in supporting its clients' drug development programs, further advancing clinical trial processes and efficiency.

In September 2023, the US Biomedical Advanced Research and Development Authority (BARDA) partnered with Ireland-based ICON plc to advance COVID-19 vaccine trials under the "Project NextGen" initiative. This project, part of BARDA's Strategic Preparedness and Response division, aims to develop vaccines and therapies for current and future COVID-19 strains. The initiative reflects BARDA's commitment to public-private partnerships, with over USD 5 billion allocated to bolster pandemic preparedness and response.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Clinical Trials Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Phase
    • 4.2.1.1. Phase I
    • 4.2.1.2. Phase II
    • 4.2.1.3. Phase III
    • 4.2.1.4. Phase IV
  • 4.2.2. By Service Type
    • 4.2.2.1. Laboratory Services
    • 4.2.2.2. Bioanalytical and Analytical Testing Services
    • 4.2.2.3. Patient Recruitment and Site Identification
    • 4.2.2.4. Clinical Trial Data Management Services
    • 4.2.2.5. Protocol Designing
    • 4.2.2.6. Medical Device Testing Services
    • 4.2.2.7. Other Services
  • 4.2.3. By Therapeutic Area
    • 4.2.3.1. Oncology
    • 4.2.3.2. Cardiology
    • 4.2.3.3. Neurology
    • 4.2.3.4. Infectious Diseases
    • 4.2.3.5. Other Therapeutic Areas
  • 4.2.4. By Application
    • 4.2.4.1. Small Molecules
    • 4.2.4.2. Vaccines
    • 4.2.4.3. Cell & Gene Therapies
    • 4.2.4.4. Monoclonal Antibodies
    • 4.2.4.5. Other Applications
  • 4.2.5. By Study Design Outlook
    • 4.2.5.1. Interventional
    • 4.2.5.2. Observational
    • 4.2.5.3. Expanded Access
  • 4.2.6. By Sponsor Type
    • 4.2.6.1. Pharmaceutical Companies
    • 4.2.6.2. Medical Device Companies
    • 4.2.6.3. Academic Institutes
  • 4.2.7. By Region
    • 4.2.7.1. North America
    • 4.2.7.2. Europe
    • 4.2.7.3. Asia-Pacific
    • 4.2.7.4. South America
    • 4.2.7.5. Middle East and Africa
  • 4.2.8. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Phase
  • 4.3.2. By Service Type
  • 4.3.3. By Therapeutic Area
  • 4.3.4. By Application
  • 4.3.5. By Study Design Outlook
  • 4.3.6. By Sponsor Type
  • 4.3.7. By Region

5. North America Clinical Trials Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Phase
    • 5.2.1.1. Phase I
    • 5.2.1.2. Phase II
    • 5.2.1.3. Phase III
    • 5.2.1.4. Phase IV
  • 5.2.2. By Service Type
    • 5.2.2.1. Laboratory Services
    • 5.2.2.2. Bioanalytical and Analytical Testing Services
    • 5.2.2.3. Patient Recruitment and Site Identification
    • 5.2.2.4. Clinical Trial Data Management Services
    • 5.2.2.5. Protocol Designing
    • 5.2.2.6. Medical Device Testing Services
    • 5.2.2.7. Other Services
  • 5.2.3. By Therapeutic Area
    • 5.2.3.1. Oncology
    • 5.2.3.2. Cardiology
    • 5.2.3.3. Neurology
    • 5.2.3.4. Infectious Diseases
    • 5.2.3.5. Other Therapeutic Areas
  • 5.2.4. By Application
    • 5.2.4.1. Small Molecules
    • 5.2.4.2. Vaccines
    • 5.2.4.3. Cell & Gene Therapies
    • 5.2.4.4. Monoclonal Antibodies
    • 5.2.4.5. Other Applications
  • 5.2.5. By Study Design Outlook
    • 5.2.5.1. Interventional
    • 5.2.5.2. Observational
    • 5.2.5.3. Expanded Access
  • 5.2.6. By Sponsor Type
    • 5.2.6.1. Pharmaceutical Companies
    • 5.2.6.2. Medical Device Companies
    • 5.2.6.3. Academic Institutes
  • 5.2.7. By Country Share
    • 5.2.7.1. United States
    • 5.2.7.2. Canada
    • 5.2.7.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Clinical Trials Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Phase
        • 5.3.1.2.1.1. Phase I
        • 5.3.1.2.1.2. Phase II
        • 5.3.1.2.1.3. Phase III
        • 5.3.1.2.1.4. Phase IV
      • 5.3.1.2.2. By Service Type
        • 5.3.1.2.2.1. Laboratory Services
        • 5.3.1.2.2.2. Bioanalytical and Analytical Testing Services
        • 5.3.1.2.2.3. Patient Recruitment and Site Identification
        • 5.3.1.2.2.4. Clinical Trial Data Management Services
        • 5.3.1.2.2.5. Protocol Designing
        • 5.3.1.2.2.6. Medical Device Testing Services
        • 5.3.1.2.2.7. Other Services
      • 5.3.1.2.3. By Therapeutic Area
        • 5.3.1.2.3.1. Oncology
        • 5.3.1.2.3.2. Cardiology
        • 5.3.1.2.3.3. Neurology
        • 5.3.1.2.3.4. Infectious Diseases
        • 5.3.1.2.3.5. Other Therapeutic Areas
      • 5.3.1.2.4. By Application
        • 5.3.1.2.4.1. Small Molecules
        • 5.3.1.2.4.2. Vaccines
        • 5.3.1.2.4.3. Cell & Gene Therapies
        • 5.3.1.2.4.4. Monoclonal Antibodies
        • 5.3.1.2.4.5. Other Applications
      • 5.3.1.2.5. By Study Design Outlook
        • 5.3.1.2.5.1. Interventional
        • 5.3.1.2.5.2. Observational
        • 5.3.1.2.5.3. Expanded Access
      • 5.3.1.2.6. By Sponsor Type
        • 5.3.1.2.6.1. Pharmaceutical Companies
        • 5.3.1.2.6.2. Medical Device Companies
        • 5.3.1.2.6.3. Academic Institutes
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Clinical Trials Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Clinical Trials Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Clinical Trials Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Clinical Trials Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Porter's Five Forces Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Clinical Trials

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 15.3.2. Novo Nordisk A/S
  • 15.3.3. IQVIA, Inc.
  • 15.3.4. Laboratory Corporation of America Holdings
  • 15.3.5. Caidya
  • 15.3.6. ICON plc
  • 15.3.7. Medpace Holdings, Inc.
  • 15.3.8. Parexel International Corporation
  • 15.3.9. Charles River Laboratories International, Inc.
  • 15.3.10. SGS Societe Generale de Surveillance SA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer